Literature DB >> 3315190

Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.

P M Terheggen1, B G Floot, E Scherer, A C Begg, A M Fichtinger-Schepman, L den Engelse.   

Abstract

Calf thymus DNA was modified in vitro by cis-diamminedichloroplatinum(II) (cisDDP), complexed with methylated bovine serum albumin and used to immunize rabbits. The anti-cisDDP-DNA antiserum obtained was applied in a double peroxidase-antiperoxidase staining procedure to localize cisDDP-DNA and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA)-DNA interaction products in cryostat tissue sections of mice and rats. Rats received cisDDP (0-10 mg/kg) and were killed after 24 h. Mice received cisDDP (0-15 mg/kg) or CBDCA (200 mg/kg), and were killed after 2 h-162 days. For each time-dose combination two mice or one rat were used; agents were given i.p. Specific nuclear staining was observed in all tissues examined from cisDDP- or CBDCA-treated animals. No significant nuclear staining could be observed in tissue sections from control rats and mice. The extent of staining after cisDDP was dose and time dependent. The lowest dose of cisDDP after which specific nuclear staining could be detected varied from tissue to tissue [e.g., 0.1 mg/kg, pancreas (mouse); 0.5 mg/kg, liver, kidney (mouse, rat)]. The longest time interval after a single dose of 6 mg/kg cisDDP in which adducts could be visualized also depended on the tissue and varied between 9 days (spleen, testis) and 162 days (kidney). The staining intensity in liver and kidney, measured microdensitometrically, decreased relatively fast in the first days after treatment, but much slower thereafter. In the kidney, cisDDP-induced DNA modification showed regional variation: inner cortex greater than outer cortex greater than medulla (rat) and cortex greater than medulla (mouse). In the mouse kidney, a small subpopulation of tubular cells in close association with the renal corpuscles showed a remarkably high staining intensity after both cisDDP and CBDCA administration. Tissues that showed clear cisDDP-induced histological alterations (kidney, pancreas, testis, and duodenum) also showed moderate to high levels of cisDDP-DNA interaction products. A correlation between cell damage (measured histologically) and cisDDP-DNA binding within one tissue type was demonstrated in the rat inner renal cortex, the murine renal cortex, and in duodenal epithelial cells of both mice and rats.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315190

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Understanding the effect of carbonate ion on cisplatin binding to DNA.

Authors:  Ryan C Todd; Katherine S Lovejoy; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2007-04-28       Impact factor: 15.419

2.  Intercellular variation in levels of adducts of aflatoxin B1 and G1 in DNA from rat tissues: a quantitative immunocytochemical study.

Authors:  C P Wild; R Montesano; J Van Benthem; E Scherer; L Den Engelse
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo.

Authors:  W DeNeve; F Valeriote; E Tapazoglou; C Everett; A Khatana; T Corbett
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

4.  Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.

Authors:  P Bergström; A Johnsson; T Bergenheim; R Henriksson
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

Review 5.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

6.  Detection of platinum-DNA adducts by 32P-postlabelling.

Authors:  F A Blommaert; C P Saris
Journal:  Nucleic Acids Res       Date:  1995-04-25       Impact factor: 16.971

7.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Effects of cisplatin and ORG.2766 in chick embryonic brain cell cultures.

Authors:  A Bruinink; F Birchler
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

9.  Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.

Authors:  P M Terheggen; B G Floot; E L Lempers; O van Tellingen; A C Begg; L den Engelse
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 10.  Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

Authors:  George D Cimino; Chong-xian Pan; Paul T Henderson
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.